Merck (MRK) announced that the FDA has accepted the biologics license application (BLA) for its investigational prophylactic long-acting monoclonal antibody, clesrovimab (MK-1654), designed to protect infants from respiratory syncytial virus (RSV) disease entering their first RSV season.With the FDA accepting the BLA for review, a decision from the regulatory body is expected on June 10, 2025.Clesrovimab is likely to be available by July 2025 in the United States.If approved, clesrovimab can help address th ...

Earlier this week, Merck (MRK) announced that it is discontinuing the development of two of its cancer candidates, vibostolimab and favezelimab. Merck was separately studying vibostolimab and favezelimab in fixed-dose combinations with its blockbuster cancer drug, Keytruda, under the KeyVibe and KEYFORM clinical development programs, respectively.Merck is discontinuing the KeyVibe-003 and KeyVibe-007 studies evaluating the fixed-dose combination of vibostolimab, an anti-TIGIT antibody and Keytruda in a non- ...

Exterior view of the entrance to Merck headquarters on February 05, 2024 in Rahway, New Jersey.Merck on Wednesday said it has snagged the rights to an experimental weight loss pill from Chinese drugmaker Hansoh Pharma, in a deal worth up to $2 billion.The oral drug has not yet entered human trials, and Merck did not specify which diseases it plans to test the drug on first. Still, it boosts the pharmaceutical company's chances of winning a slice of the booming obesity drug market, which some analysts expect ...

Merck (MRK) decided to discontinue two clinical development programs, namely KeyVibe and KEYFORM, which are evaluating its investigational cancer drugs vibostolimab and favezelimab, respectively.Merck’s decision followed a series of setbacks for both drugs, which were being tested in combination with its blockbuster drug Keytruda for various cancer indications across multiple late-stage studies. After a detailed review of data from the clinical studies on both drugs, management has decided to focus on its o ...

Merck & Co. (NYSE: MRK ) has seen significant changes in its financial performance and market position through 2024. In this article, I attempt to provide investors with a comprehensive analysis of MRK's past business performance, future growth prospects, and its competitiveYavuz Akbay is quantitative analyst with over 5 years of experience in interpreting complex financial data, developing complex mathematical models and modeling and forecasting. Utilizes machine learning algorithms to enhance financial an ...

Merck (MRK) announced that EMA’s Committee for Medicinal Products for Human Use (“CHMP”) recommended granting conditional approval to its oral HIF-2α inhibitor, Welireg (belzutifan), for use in two indications associated with renal cell carcinoma (“RCC”).The CHMP recommended Welireg to treat adult patients with von Hippel-Lindau (“VHL”) disease who require therapy for associated RCC, central nervous system hemangioblastomas or pancreatic neuroendocrine tumors, not requiring immediate surgery. This committee ...

The primary goal of the Cash Flow Kingdom Income Portfolio is to produce an overall yield in the 7—10% range. We accomplish this by combining several different income streams to form an attractive, steady portfolio payout. The portfolio's price can fluctuate, but the income stream remains consistent. Start your free two-week trial today!Merck & Co., Inc. (NYSE: MRK ) is a leading pharma company with an attractive drug portfolio that has seen its shares decline significantly in the recent past. This has made ...

Merck (MRK) ended the recent trading session at $101.25, demonstrating a +1.5% swing from the preceding day's closing price. The stock outperformed the S&P 500, which registered a daily loss of 0.54%. At the same time, the Dow lost 0.53%, and the tech-heavy Nasdaq lost 0.66%.Shares of the pharmaceutical company have appreciated by 1.27% over the course of the past month, outperforming the Medical sector's loss of 4.6% and lagging the S&P 500's gain of 1.5%.Analysts and investors alike will be keeping a clos ...

Merck & Co., Inc. (NYSE:MRK) 7th Annual Evercore ISI HealthCONx Conference December 3, 2024 1:20 PM ET Company Participants Peter Dannenbaum - SVP, IR Eliav Barr - Chief Medical Officer Conference Call Participants Umer Raffat - Evercore ISI Umer Raffat Okay. Excellent. Thank you guys for joining us. Super excited to have Merck Management with us. Just before, I dig into my specific questions, I'll let you, frame the broader discussion. We'll jump right in. Eliav Barr Well, great. It's great to be here. M ...

Merck & Co., Inc. (NYSE:MRK) 7th Annual Evercore ISI HealthCONx Conference December 3, 2024 1:20 PM ET Company Participants Peter Dannenbaum - SVP, IR Eliav Barr - Chief Medical Officer Conference Call Participants Umer Raffat - Evercore ISI Umer Raffat Okay. Excellent. Thank you guys for joining us. Super excited to have Merck Management with us. Just before, I dig into my specific questions, I'll let you, frame the broader discussion. We'll jump right in. Eliav Barr Well, great. It's great to be here. M ...